SCHEMBL4773152

SCHEMBL4773152

Clc1nc(-c2ccc3c(c2)OCCO3)cc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.48
NPC1 O15118 8/20 0.48
RAB9A P51151 8/20 0.48
MAPT P10636 7/20 0.48
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 6/20 0.48
PKM P14618 2/20 0.48
TP53 P04637 5/20 0.46
LMNA P02545 3/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
DHODH Q02127 1/20 0.45
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
ADORA3 P0DMS8 1/20 0.45
HTT P42858 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768952 0.91 KDM4E (0.56) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL13731215 0.79 ALDH1A1 (0.47) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL31388225 0.74 MEN1 (0.55) SMN1; SMN2RAB9AMAPTALDH1A1KDM4E
SCHEMBL786133 0.74 MEN1 (0.55) SMN1; SMN2RAB9AMAPTALDH1A1KDM4E
SCHEMBL509599 0.74 ADORA1 (0.62) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL6292092 0.72 CYP1A2 (0.45) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL21451444 0.72 NPC1 (0.56) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL4767456 0.72 AGTR1 (0.45) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL7258823 0.72 CYP19A1 (0.47) SMN1; SMN2NPC1RAB9AMAPTALDH1A1
SCHEMBL7004020 0.72 SMN1; SMN2 (0.83) SMN1; SMN2NPC1RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 SMN1; SMN2 27/4885NPC1 4578/4885RAB9A 2421/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 SMN1; SMN2 37/4885NPC1 4576/4885RAB9A 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.